5 July 2024
Incanthera
plc
("Incanthera" the
"Company")
Investor
Evening
Aquis Stock Exchange and
Investor Hub
Incanthera plc (AQSE:INC), the
company specially focused on innovative technologies in dermatology
and oncology, is pleased to announce its participation in "The Pub
Test" Investor Evening. This event is co-hosted by the Aquis
Exchange and InvestorHub and will take place on Wednesday, 17th
July 2024 at Samuel Pepys, Stew Ln, London EC4V 3PT, starting at
6:00 PM.
The Company's Chairman, Tim McCarthy,
will engage in a fireside conversation designed especially for
private investors. This setting offers a unique opportunity for
attendees to interact directly with company executives, ask
questions, and network with fellow investors.
All attendees will have the chance to
network over drinks and a buffet.
To register for the event, please use
the following link: https://events.humanitix.com/the-pub-test-or-london-july-4-2024
Commenting on the event, Tim
McCarthy, said:
"We
have been fortunate to attend and present at a number of investor
events recently and we always receive invaluable feedback and
commentary from engaging with our shareholders and
supporters.
We
value the opportunity to share our vision and answer any questions
investors may have at this event for shareholders, potential
shareholders, and stakeholders. Co-hosted by Aquis Exchange and
Investor Hub, we know it will be a great
evening."
RNS Reach is a non-regulatory news
service. By using this service an issuer is confirming that the
information contained in this announcement is of a non-regulatory
nature.
**ENDS**
For further information please
contact:
Notes to Editors
About Incanthera plc
Incanthera is a specialist company
focused on innovative technologies in dermatology and
oncology. It seeks to identify and develop innovative solutions to
current clinical, commercially relevant unmet needs, utilising new
technology from leading specialists and academic institutions as
well as its in-house development team.
The Company originated from
the Institute of Cancer Therapeutics ("ICT") at
the University of Bradford. Incanthera's strategy
is to develop each candidate in its portfolio from initial
acquisition or discovery to securing its future through
commercially valuable partnerships at the earliest opportunity in
its development pathway.
For more information on the Company
please visit: www.incanthera.com
@incantheraplc